Aclaris Therapeutics, Inc. 4
4 · Aclaris Therapeutics, Inc. · Filed Nov 18, 2016
Insider Transaction Report
Form 4
VIVO VENTURES VII, LLC
10% Owner
Transactions
- Sale
Common Stock
2016-11-16$27.30/sh−9,765$266,585→ 79,635 total(indirect: By Vivo Ventures VII Affiliates Fund, L.P.) - Sale
Common Stock
2016-11-18$22.72/sh−440,402$10,005,933→ 3,213,532 total(indirect: By Vivo Ventures Fund VII, L.P.) - Sale
Common Stock
2016-11-18$22.72/sh−9,598$218,067→ 70,037 total(indirect: By Vivo Ventures VII Affiliates Fund, L.P.) - Sale
Common Stock
2016-11-16$23.25/sh−448,063$10,417,465→ 3,653,934 total(indirect: By Vivo Ventures Fund VII, L.P.)
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $24.90, inclusive. The reporting person undertakes to provide to Aclaris Therapeutics, Inc., any security holder of Aclaris Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- [F2]Vivo Ventures VII, LLC ("VV LLC") is the general partner of Vivo Ventures Fund VII, L.P. ("VVF"), the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. In addition, each of Albert Cha, a director of the issuer, Frank Kung and Edgar Engleman is a managing member of VV LLC and may be deemed to share voting and dispositive power over the securities held by VVF. Each of such individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
- [F3]VV LLC is the general partner of Vivo Ventures VII Affiliates Fund, L.P. ("VVAF"), the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. In addition, each of Albert Cha, a director of the issuer, Frank Kung and Edgar Engleman is a managing member of VV LLC and may be deemed to share voting and dispositive power over the securities held by VVAF. Each of such individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.